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Following the demonstration by Rygaard and
Povlsen (1969) that human tumours could be grown
in congenitally athymic mice and the subsequent
use of thymectomised, whole-body irradiated mice
suitable for tumour heterotransplantation (Castro,
1972), large numbers of serially transplantable
human tumour xenograft lines have been
established (Shimosato et al., 1976, Povlsen et al.,
1978; Giovanella et al., 1978). In spite of extensive
data on the establishment, biological characteristics
and drug response of these xenografts, their clinical
relevance is not yet clear. There is an increasing
body of evidence to suggest that xenografts of a
particular tumour type (e.g. chorion carcinoma,
Burkitt's lymphoma) are sensitive to the
chemotherapeutic agents active clinically in these
diseases (Povlsen & Rygaard, 1974; Hayahashi et
al., 1978). There is also evidence that a xenograft
line retains the same spectrum of chemosensitivity
as the individual patient from whom the original
tumour was obtained (Shorthouse et al., 1980;
Nowak et al., 1978). One potential use of this
system is the testing of an individual patient's
tumour for response to a variety of cytotoxic drugs
(Povlsen, 1978).
In a review article by Double in (1975) it was
suggested that use of xenografts in chemotherapy
testing might be as a secondary screen for new
agents rather than as a test for individual patient's
tumours, but it seemed possible that improvements
in technique might have invalidated this prediction.
We therefore analysed our data with regard to five
tumour types extensively studied at our laboratories
to assess whether xenografts could be used for
individual patient drug sensitivity testing.
Throughout this study, immunosuppressed
CBA/lac mice were used for tumour implantation.
The immunosuppression was effected by
thymectomy at 4 weeks of age, followed by 9 Gy
whole-body irradiation 4-8 weeks later. The mice
Correspondence: M.J. Bailey, St George's Hospital,
Blackshaw Road, London, S.W.17.
Received 8 July 1984; accepted 16 August 1984.
were protected against the otherwise lethal effect of
radiation by an intra-peritoneal injection of
200mgkg-1 of cytosine-arabinoside given 48 h
prior to exposure (Steel et al., 1978). Specimens of
primary and metastatic tumour were collected at
surgery on patients at the Royal Marsden Hospital
and other collaborating hospitals. Specimens were
placed in transport medium at 4°C and taken to the
laboratory for implantation with a minimum
possible delay. Only viable specimens from
histologically proven tumours were used. Frozen
sections were obtained routinely in patients with
breast cancer, but not always in other tumour
types.
Pieces of tumour between 2 and 5mm diameter
were implanted into s.c. pocket over the flank of
each animal within one week of
immunosuppression. At least one representative
portion was sent for histology to confirm that
viable tumour was being implanted. Each mouse
was regularly inspected for signs of tumour growth
for a period of one year. When progressive growth
ensued, the tumour was allowed to reach a size of
- 1 cm diameter, after which the mouse was killed
and the tumour excised. The tumour was then
divided into cubes, and transplanted into as many
immunosuppressed mice as tumour bulk permitted
(usually 10-20). Several cubes were examined
histologically.
Drug testing was carried out using a control
group of 5-10 tumour bearing mice, and groups of
5-10 mice with tumours for each drug to be tested.
Testing was performed on the earliest passage at
which sufficient tumour bearing mice could be
produced.
All patients were followed by personal interview
and examination for at least one year, or until the
patient died. Further details of implantation
technique, histological methods and
chemosensitivity testing have been published
elsewhere (Bailey et al., 1980b; Raghaven et al.,
1980a, 1980b; Selby et al., 1979, 1980; Jones et al.,
in preparation; Shorthouse et al., 1980). Specimens
from 339 patients were implanted and shown to
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Table I Number of serially transplantable xenografts
established by tumour type
Viable
specimens
Total viable from Serially
Tumour specimens untreated transplantable
type implanted patients lines
Breast
carcinoma 91 91 9
Testicular
teratoma 46 34 11
Ovarian
carcinoma 37 20 7
Bronchogenic
carcinoma 49 48 38
Melanoma 16 10 10
Overall 239 203 75
Table II Clinically usable lines established by tumour type.
Lines in which Lines with low
Number of donor patients take rate or
Tumour transplantable died before long doubling Useful
type lines testing time takes
Breast
carcinoma 9 0 3 6
Testicular
teratoma 11 2 2 7
Ovarian
carcinoma 7 4 1 2
Bronchogenic
carcinoma 38 29 4 5
Melanoma 10 5 1 4
Overall 75 40 11 24
contain viable tumour on histological review. From
these implants, 75 serially transplantable xenograft
lines have been established, an overall take risk of
31%. The take rate varied considerably from one
tumour type to another, the lowest being breast
carcinoma (10%), the highest being bronchial
carcinoma (77%) (Table I). Of the 239 patients
from whom specimens were implanted, 201 had not
had previous chemotherapy, although some had
received radiotherapy. Certain tumour implants,
such as those of melanoma and ovary were
sometimes derived from patients with very
advanced disease and these patients have been
excluded from our final analysis so as not to bias
the results by inclusion of patients with a short life
expectancy. The 75 xenograft lines produced 24
lines which could have yielded chemosensitivity
data prior to the patient's death. Of the remaining
lines, some were so slowly growing with such a low
take rate after serial passage as to prevent
chemotherapy testing. In others the patient had
died before such testing could be carried out.
Therefore, out of the 239 patients, 24 could have
had chemosensitivity testing performed prior to
their death (10%). Excluding patients with
advanced disease and those who had been
previously treated, 11% overall (22/201) could have
been tested (Table II). The proportion of usable
takes (in terms of drug sensitivity testing) varied
from 6.6% for breast carcinoma to 25% for
malignant melanomas.
The overall take rate in our series refers to
serially transplantable xenograft lines and was 31%.
This is very similar to the results obtained by other
groups with an extensive experience of human
tumour xenografting, whether using nude orXENOGRAFTS IN INDIVIDUAL PATIENT DRUG TESTING 723
immunosuppressed mice with published take rates
of between 12 and 26% (Shimosato et al., 1976;
Povlsen, 1978; Giovanella et al., 1978).
Work undertaken at our institute has shown no
difference in take rates between the
immunosuppressed mouse used in these studies and
the congenitally athymic mouse often used as an
alternative (Steel et al., 1978; Bailey et al., 1980 ).
Considerable effort has been directed towards
raising the take rate but no dramatic increase in
establishing serially transplantable human tumour
lines has occurred to suggest that the overall take
rate of 31% can be improved.
We have defined a "Usable take" for the
purposes of this paper as being a xenograft line
established from a human tumour and maintaining
histological and karyotypic characteristics of that
tumour in serial passage in immunosuppressed
mice, which, by virtue of passage, could be
implanted into sufficient mice to allow
chemotherapy trials to be undertaken yielding
results within the lifespan of the donor patient.
We have therefore excluded from our analysis
patients whose disease at the time of implantation
to the mice was so advanced as to render any
prospect of their survival until xenograft testing
could be performed unlikely. Even so, only 11% of
the patients whose tumours were implanted had
xenograft lines established which could have yielded
useful drug sensitivity data before their death. It
may be that the reason so few patients could have
benefited from drug testing is that patients with less
aggresive tumours who survived long enough for
testing to have been possible had a low xenograft
take rate. Table III shows the take rate of each
tumour type compared with 3 and 5 year crude
survival figures. It can be seen that in general
terms, the more lethal the tumour, the more likely
it is to be established successfully as a xenograft.
The expense involved in drug testing using the
xenograft model is considerable - the cost of mice
alone, excluding feeding, housing, salaries of
technicians and clinicians involved would have been
£400 per tumour tested for 3 drugs assuming
optimal take rates in passaging, and 100% animal
survival. (The immunosuppressed mice used in our
laboratories are -25% of the cost of nude mice
used in many laboratories, but require more
technical expertise to prepare). The cost of testing
more than three drugs would be proportionally
higher and to be clinically useful, as many as 6-10
drugs would need to be examined. A realistic
estimate to include salaries and multiple drug
testing, but still excluding capital cost would be in
the order of £2000 per tumour tested.
The human tumour xenograft has many
applications in cancer research, including the
evaluation of new cytotoxic drugs, the study of
tumour markers, development of tumour specific
antibodies, tumour radiolocalisation, cell kinetics
and experimental pathology. However, our results
show that even assuming that xenografted tumours
maintain the drug sensitivity of the original tumour
in the patient, the place of the xenograft model for
individual patient drug testing is limited by the
small proportion of patients who might benefit and
the necessarily long delay between implantation of
the surgical specimen and chemotherapy results
becoming available. This period was seldom shorter
than 30 weeks and usually in excess of 50 weeks.
This would be acceptable in patients with breast
cancer, who often do not require chemotherapy for
recurrent disease for many years, but exceeds the
median survival of patients with bronchogenic
carcinoma. Therefore, if drug testing results became
available during the course of the disease, it would
only be at a very late stage. For these reasons, we
feel that serially transplantable human tumour
xenografts are unlikely to be of value in individual
patient drug sensitivity testing.
Table III Percentage take rate compared with 3- and 5-
year survival rates for the 5 tumour types studied
Tumour Take rate as Overall survival
types xenograft (%) 3 years (%) 5 years (%)
Breast 10 70 50
Ovary 19 40 25
Teratoma 24 45 40
Melanoma
(recurrent) 63 20 10
Bronchus 75 6 4724 M.J. BAILEY et al.
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